(Q44507814)

English

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea (English)

1 reference

Europe PubMed Central

3 December 2017

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Barry J Goldstein

1

1 reference

Europe PubMed Central

3 December 2017

Miranda Pans

2

1 reference

Europe PubMed Central

3 December 2017

Cindy J Rubin

3

1 reference

Europe PubMed Central

3 December 2017

publication date

1 March 2003

1 reference

Europe PubMed Central

3 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

3 December 2017

25

1 reference

Europe PubMed Central

3 December 2017

3

1 reference

Europe PubMed Central

3 December 2017

890-903

1 reference

Europe PubMed Central

3 December 2017

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Testing whether an identified treatment is best

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative tolerability profiles of oral antidiabetic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The treatment of type II diabetes in Texas. Current issues for managed care and employers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980112-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80112-1

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44507814&oldid=2025951799"